VRNA News and Press, Verona Pharma plc From 03/07/23

Transformational results in Phase 3 ENHANCE program for COPD NDA submission expected Q2 2023 Strong balance sheet to support planned US commercial launch Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., March 07, 2023 (GLOBE NEWSWIRE...

LONDON and RALEIGH, N.C., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the four...

Summary Verona Pharma is a UK-based biotech with a $1.6Bn market cap developing a phase 3 asset targeting COPD. Ensifentrine is a novel phase 3 inhaled selective dual inhibitor of PDE3 and PDE4 targeting COPD, which is a $10Bn indication with a high unmet need. Verona Pharma has a s...

Summary Verona Pharma plc's primary endpoint and all key secondary endpoints met in second phase 3 study known as ENHANCE-1; Ensifentrine was used to treat patients with chronic obstructive pulmonary disease. NDA filing of ensifentrine to the FDA for the treatment of patients with chron...

Summary Small caps outperformed the Nasdaq Composite last year as stocks fell due to the Federal Reserve's efforts to control inflation. Market fears are mounting that the economy may slip into a recession, but there are opportunities in small-cap stocks. The potential risk of a lon...

Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...

Summary Verona Pharma is a biopharmaceutical company involved in studies and product development related to respiratory diseases. Ensifentrine is the main company product and is based on the analysis of great unmet medical demand in COPD. The latest clinical trials on Ensifentrine u...

Summary Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half. Biotechnology should be favorably positioned relative to the market if the economy slips into a recession. Biotech fortunes near term are to be determined by the ...

Summary Expect the unexpected has been a common theme over the past two years as global economies and markets reel from a pandemic and the war in Ukraine. June 2022 posted some of the worst performance in decades, with the S&P 500 -21%, DJIA -15%, and trillions erased since 2021 pea...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips With the healthcare sector poised to grow significantly in the coming years, healthcare stocks to buy present a fantastic opportunity for investors. Healthcare is something that everyone will need at some point in their lives, ...